Antihypertensive Effects of Sacubitril/Valsartan Versus Olmesartan: An Updated Systemic Review and Meta-Analysis of Randomized Controlled Trials
Roomi Raja, Sandhya Kumari, Muhammad Umer Khan, Araib Ayaz, Duaa Jaffar, Zain Mohamad, Muhammad Ali Muzammil, Nasira Sohail, Saad Ahmed Qureshi, Hamid Saeed, Muhammad Fahad Amin, Ansar Jawad, Giustino Varrassi, Satesh Kumar, Mahima Khatri, Areeba Maryam · 2023
Read Antihypertensive Effects of Sacubitril/Valsartan Versus Olmesartan: An Updated Systemic Review and Meta-Analysis of Randomized Controlled Trials by Roomi Raja, Sandhya Kumari, Muhammad Umer Khan, Araib Ayaz, Duaa Jaffar, Zain Mohamad, Muhammad Ali Muzammil, Nasira Sohail, Saad Ahmed Qureshi, Hamid Saeed, Muhammad Fahad Amin, Ansar Jawad, Giustino Varrassi, Satesh Kumar, Mahima Khatri, Areeba Maryam (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10715627.txt.
Description
Sacubitril/valsartan is a drug commonly prescribed for the management of hypertension. However, the complete understanding of its efficacy and safety as an antihypertensive agent remains a subject of ongoing investigation. To address this gap, a meta-analysis was conducted to assess and compare the efficacy and safety of sacubitril/valsartan in relation to olmesartan, an angiotensin receptor blocker (ARB).
Catalog record
| CREATOR | Roomi Raja, Sandhya Kumari, Muhammad Umer Khan, Araib Ayaz, Duaa Jaffar, Zain Mohamad, Muhammad Ali Muzammil, Nasira Sohail, Saad Ahmed Qureshi, Hamid Saeed, Muhammad Fahad Amin, Ansar Jawad, Giustino Varrassi, Satesh Kumar, Mahima Khatri, Areeba Maryam |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |